FDA Targets GLP 1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for Peptide Therapy in Austin, TX Austin Plastic Surgeon Dr. Chuma People are turning themselves into lab rats': the injectable peptides craze sweeping the US Well actually The Guardian Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law